Clinical and Experimental Pharmacology and Physiology

Cover image for Vol. 42 Issue 9

Edited By: Prof Jun-Ping Liu

Impact Factor: 2.405

ISI Journal Citation Reports © Ranking: 2013: 38/81 (Physiology); 118/256 (Pharmacology & Pharmacy)

Online ISSN: 1440-1681


Author Guidelines




Author Guidelines


Why publish in Clinical and Experimental Pharmacology and Physiology?

Quick decision and rapid peer review, with the final decision currently reached in an average of 25 days.

Fast publication. Your article will be published and indexed online within two weeks of acceptance.

Fair and rigorous peer review from the journal’s expert editors, with clear revision instructions provided.

Unlimited colour publication of figures, at no charge to authors.

Open Access publishing. Authors can choose to publish open access and employ the rights associated with creative commons licences

Optimization of discoverability. Articles published in the journal benefit from the discoverability of content published on the Wiley Online Library platform.


1. MANUSCRIPT SUBMISSION
Please read the complete Author Guidelines carefully prior to submission, including the section on copyright.

Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at http://mc.manuscriptcentral.com/cepp.


2. EDITORIAL AND CONTENT CONSIDERATIONS

Aims and Scope
Clinical and Experimental Pharmacology and Physiology provides a medium for the rapid online publication of original research papers, rapid communications, and technical papers on the results of clinical and experimental work in pharmacology and physiology. Reviews, research highlights and news/views are also published.

The journal aims to make a substantial contribution to effective and productive communication between scientists throughout the world who are working in these interrelated disciplines. Clinical and Experimental Pharmacology and Physiology has been endorsed by the High Blood Pressure Research Council of Australia (HBPRCA), the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Australian Physiological Society (AuPS).

Editorial Review and Acceptance
Submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. In most cases, manuscripts are peer reviewed by at least two anonymous reviewers. A manuscript may be rejected without review, however, if the Editor-in-Chief deems it inappropriate for the journal. The content of the manuscripts will be held in strict confidence by the editors. The decision to accept or reject rests with the Editors. Where contributions are judged as acceptable for publication on the basis of content, the Editor and the Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

New Pathways: Transferred and Expedited Peer Review. The Editors are able to offer expedited peer review for papers that have already been through the review process with a number of select journals. If you have an original article that has been found not to be acceptable for publication by one of a small number of journals on the basis of a perceived lack of priority rather than major flaws in scientific rigour, you may wish to consider using our 'New Pathways' review option. A full list of these journals, along with detailed instructions for submission and information about the expedited review of such manuscripts, can be found online. Articles should be submitted in their original form along with a copy of the decision letter from the journal. The decision letter should include at least two sets of reviewer comments. These manuscripts will then receive expedited review by the Editor.

Subjects covered
Contributors are invited to submit manuscripts as Original Articles, Review, Technical Papers, Rapid Communications and Letters to the Editor. The content of these papers may be in any of the fields that are covered by the title Clinical and Experimental Pharmacology and Physiology, interpreted in the broadest sense. The journal particularly welcomes papers within the broad subject of translational medicine and has a policy of not publishing papers describing studies of the effects of impure natural substances. Experimental studies that provide new mechanistic insights are given priority over those that are largely descriptive.

When submitting your manuscript, please select the manuscript type that most closely fits with the topic of your paper. The manuscript will be allocated to one of the associate editors listed below, chosen by the Editor-in-Chief. Original Article-Other may be selected if your paper does not fall within one of these topics.

Ageing: Xiang-Mei Chen
Cardiovascular-Vascular: Grant Drummond
Oxidative Stress: Reiko Inagi
Receptor Signaling: Hui-Yao Lan
Neurobiology: Jian-Sheng Lin
Kidney: Akira Nishiyama
Epidemiology, Clinical Trials and Public Health: Christopher Reid
Hormones, Metabolisms, Diabetes, Obesity: John Speakman
Cancer: Dawei Xu
Drug Discovery, Metabolism, Transport: Shu-Feng Zhou

Ethical Considerations
The journal is committed to integrity in scientific research and recognizes the importance of maintaining the highest ethical standards.

Use of Human and/or animal subjects
Investigations in human subjects must conform to the International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS/WHO). Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used, and the fact that such consent has been given should be recorded in the paper. Patient anonymity should be observed.

Experiments using animals must adhere to internationally accepted guidelines for the use of animals in research (e.g. CIOMS Guidelines) and the highest acceptable standard of ethical practice. Currently, these are the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. The Code is obtainable from the Secretary, NHMRC, PO Box 9848. Canberra, ACT 2601 Australia.

The alternative is to use the CIOMS Guidelines. The purpose of the experiments must have been to obtain significant scientific information relevant to humans or other animals. Authors must declare, either in a covering letter or in the paper itself, whether or not prior approval for experiments was obtained from an animal experimentation ethics committee, animal care and use committee, equivalent committee or relevant body in the country of question. The name of the committee or relevant body must be included. Papers from countries where such committees are not established, or if such evidence is not provided, must conform to the relevant Australian Guidelines. Currently these are Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.

Anaesthetic, analgesic or other measures taken to reduce or abolish any pain or discomfort must be detailed. If death or serious injury is used as an experimental end-point, the paper must indicate why such end-points were essential. Neuromuscular blocking agents must not have been used without appropriate general anaesthesia, except in animals in which sensory awareness had been eliminated. Techniques and procedures that minimize the use of live animals must have been adopted where feasible and appropriate. The statistical methods should have ensured the use of the minimum number of animals compatible with valid experimentation. Clinical and Experimental Pharmacology and Physiology retains the right to reject any manuscript on the basis of unethical conduct of either human or animal studies.

Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for important intellectual content; iii) Final approval of the version to be published; and iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.

Disclosure
Authors should declare any financial support or relationships that may pose a conflict of interest in the Covering Letter and in the manuscript under acknowledgements. If there is nothing to declare, a sentence should be included stating so.

Clinical Trials Registry
Registration in a public trials registry at or before the onset of patient enrolment is required. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we request registration by April 1, 2006. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as studies on pharmacokinetics or major toxicity (e.g. phase 1 trials), are exempt. We do not advocate one particular registry. The registry should meet the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian Clinical Trials Registry; (4) the Chinese Clinical Trials Register; and (5) the Clinical Trials Registry - India; (6) University Hospital Medical Information Network (UMIN).

Randomized Control Trials
Reporting of randomized controlled trials should follow the guidelines of the Consort Statement.

Publication Ethics
Plagiarism Detection. The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Committee on Publication Ethics. The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).



3. MANUSCRIPT CATEGORIES

Editorial Commentaries (by invitation only)
• Word Limit: 2000 words
• Abstract: No abstract
• References: Up to 10
• Description: Proposals for Editorial Commentaries may be submitted for consideration. An outline of the proposed Editorial Commentary should be submitted in the first instance rather than the full text.

Reviews
• Word limit: 6000 words, including Title Page, Abstract, Text, References and Tables
• Abstract: 250 words maximum
• References: Up to 120 Figures/tables: Maximum 8.
• Description: Reviews are comprehensive analyses of specific topics. Proposals for reviews may be submitted with an outline of the proposed paper, the abstract and the author’s publication list for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

Research highlights (by invitation only)
• Word Limit: 3000 words, including Title Page, Abstract, Text, References and Tables
• Abstract: 250 words maximum
• References: Up to 80
• Figures/Tables: Maximum 4
• Description: Research Highlights are invited on a particular topic and an editor is appointed to oversee the peer review process. The manuscripts are presented in the form of a mini-review. Original data may be included, but if so, sufficient detail on methods must be provided so that proper peer review can be accomplished. Further instructions are provided upon invitation.

Original Articles
• Word limit: 6000 words, including Title Page, Abstract, Text, References and Tables Abstract: 250 words maximum
• References: Up to 60
• Figures/tables: Maximum 8
• Description: Full-length reports of current research in any of the fields covered by the title Clinical and Experimental Pharmacology and Physiology, interpreted in the broadest sense. The text should be arranged as follows: Abstract, Introduction, Results, Discussion, Methods, Acknowledgements, References. Supporting information should be provided in a separate file.

New pathways: Transferred Peer Review. Please read the section 'New Pathways: Transferred Peer Review' above for information on submitting original articles along with reviews from selected other journals. More details on the CEPP New Pathways program can be found here.

Technical Paper
• Word Limit: 6000 words, including Title Page, Abstract, Text, References and Tables
• Abstract: 250 words maximum
• References: Up to 60
• Figures/tables: Maximum 8
• Description: Technical Papers should be based mainly on the presentation of new techniques, or the testing or critique of existing techniques. These should be structured like Original Articles.

Rapid Communications
• Word limit: 3000 words (excluding references)
• Abstract: maximum 250 words
• Figures/ tables: 4 maximum
• References: 60 maximum
• Description: Rapid Communications report most important new findings and are given priority by the Editorial Office. The text should include Abstract, Introduction, Results, Discussion, Methods, Acknowledgements and References. Authors should indicate the reasons for Rapid publication.

Letters to the Editor
• Word limit: 1200 words
• Abstract: 120 words
• References: Up to 30
• Figures/ tables: 2 maximum
• Description: Letters may be submitted to the Editor on any topic of short cutting edge research. Comments on papers recently published in CEPP will be welcomed. They should include a brief summary and key words, but no subheadings. Name, postal address, telephone, facsimile numbers and email addresses of the corresponding author should be given on the title page.

Letters to the Editor are not subjected to external peer review, but will be reviewed by at least one editor or editorial board member. Submissions may be edited for length, grammatical correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or response. Letters that offer perspective on content already published in the Journal can use an arbitrary title, but a response from authors must cite the title of the first Letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion.



4. PREPARING YOUR MANUSCRIPT

Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author. Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.

Optimising Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.

Manuscript Format and Style
Manuscripts should follow the style of the Vancouver agreement detailed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, as presented in JAMA 1997; 277: 927-34.

Spelling
The Journal uses UK spelling and authors should follow the latest edition of the Oxford Concise English Dictionary.

Footnotes
Footnotes arising from the text must not be used.

Standard abbreviations
These should be used sparingly. They should be defined in the Summary and on the first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader.

Units of measurement
As far as possible, these should conform to the SI conventions, with the notable exception that blood pressures should be given in mmHg. It is strongly recommended that contributors consult the booklet Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. D. N. Baron), 1988, The Royal Society of Medicine Services, London. The recommendations outlined therein will be followed.

Methods of statistical analysis
The journal recommends that investigators seek the advice of a professional biostatistician in the design stage of their study, as well as during the stage of actual data analysis. Statistical methods used should be identified, with appropriate citation of statistical texts or articles that describe their use. Reasons for choosing particular methods of analysis, and for the number of experimental units, should be stated. The name and source of commercial statistical computer packages used should be identified. The statistical section should contain sufficient detail for the reader to have a clear idea about how the analysis was performed. The level of statistical significance (alpha) should be defined and it should be stated explicitly whether this refers to one- or two-sided probability. Nevertheless, exact P values should be given to a sensible number of significant figures (e.g. P = 0.01 rather than P = 0.0058). The risk of type 1 error (a false positive inference) should always be controlled. This requires the use of global statistical tests of significance where possible, particularly in experimental designs that involve repeated measurements in the same experimental units (humans, animals, tissues or cells). Multiple comparisons within a single experiment should only be made when this is absolutely necessary and, if so, P values should be conservatively corrected to control the risk of type 1 error. Two techniques that provide excellent control of the type 1 error rate are the 'false discovery rate' procedure (Curran-Everett D, Benos DJ. Guidelines for reporting statistics in journals published by the American Physiological Society. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004; 287: R247-9) and the Ryan-Holm stepdown Bonferroni procedure (Ludbrook J. Multiple comparison procedures updated. Clin. Exp. Pharmacol. Physiol. 1998; 25: 1032-7). Confidence intervals may be used in addition to P values.

Data should be expressed as mean (SD) when the intention is to indicate the degree of variability of the data around the mean value, and as mean ± SEM when the intention is to estimate the population mean from the sample data. In either case, the numbers of observations (n) should be stipulated. This allows the reader to calculate SD from SEM and vice versa. (For further reading, see Ludbrook J. Comments on journal guidelines for reporting statistics. Clin. Exp. Pharmacol. Physiol. 2005; 32: 324-6 (Letter). Detailed guidelines on the use and presentation of statistics in Clin. Exp. Pharmacol. Physiol. can be found online.

Chemical substances
These must be properly identified. Except for standard laboratory chemicals, the source of supply must be given. Drug nomenclature should follow the rules of the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, published in various articles in Pharmacological Reviews. Proprietary names should be avoided unless the paper is concerned with a specific formulated product, in which case the nature of the formulation should be stated. Isotopically labelled chemicals should be identified by the atomic number and symbol of the isotope, its location in the molecule and the specific activity in standard (SI) units.

Receptors
For receptor types, nomenclature should also follow the conventions established by the IUPHAR Committee on Receptor Nomenclature and Drug Classification (International Union of Basic and Clinical Pharmacology), which are published in Pharmacological Reviews.

Parts of the Manuscript
Manuscripts should be presented in the following order: (i) Title Page, (ii) Abstract and keywords, (iii) Introduction, (iv) Results, (v) Discussion, (vi) Methods, (vii) Acknowledgements (including disclosure), (viii) References, (ix) tables (each table complete with title and footnotes), (x) figure legends and (xi) figure. Supporting Information should be supplied as a supplementary file.

The first page of the manuscript should contain the following information:

Title: The title should be as informative as possible but should avoid over-detailed information about the experimental procedures. Titles should not exceed 250 characters (including spaces).

Family name for each author, preceded by initial(s) or given name(s): That part of each family name which is to appear in indexes must be underlined.

Laboratory or Institute: The official name (in English) of each place in which the work reported in the manuscript was carried out should be given, together with the larger organization (if applicable), city, state (if applicable) and country.

Short title: This will be used as a running heading in the printed text; it must not exceed a total of 45 characters (including spaces) and should be as informative as possible within this limit. Abbreviations should be avoided if possible.

Author for correspondence: The name and full postal address, facsimile, telephone and email details of the corresponding author must be provided and clearly identified. All correspondence regarding the manuscripts, proofs and requests for reprints will be sent to this author, using the contact details provided.

Present addresses of authors: Should the addresses of other authors differ from that of the author for correspondence, this information should be provided and will be published.

Abstract and keywords
Abstract. This should commence on page two and consist of a continuous paragraph, describing the aim of the study, what was done, the main findings and the conclusions reached. A limit of 250 words applies to article abstracts, and 120 for Letters to the Editor.

Key words: These are required for indexing the content of the paper, and should, if possible, be selected from the US National Library of Medicine's Medical Subject Headings (MeSH) browser list. A maximum of 10 words or phrases should be sufficient. Key words should be arranged in alphabetical order.

References: Up to 60
Figures/tables: Maximum 8
Description: Technical Papers should be based mainly on the presentation of new techniques, or the testing or critique of existing techniques. These should be structured like Original Articles.

Introduction
This section should commence on a new page and contain a concise statement of the reason for doing the work, and should not contain a major statement about either the findings or the conclusions.

Results
The findings should be presented clearly with adequate reference to figures and tables. The text of Results and the information contained in figures and tables should complement one another; repetitive presentation of the same data should be avoided. Material appropriate to Discussion should not be included in Results. However, brief comments on minor points are acceptable if they help to consolidate the new information being presented or if they assist the reader to follow the progression of ideas in moving from one set of data to another.

Discussion
This should not be a mere reiteration of the Results. It should deal with the relationship of the new information given in Results to the corpus of knowledge in that field, and should be pertinent to the data presented. The main conclusions should be incorporated in the final paragraph.

Methods
Sufficient information should be given to permit the work to be repeated in other clinics or laboratories.

Acknowledgements
The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of colleagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not appropriate.

References
Must follow the Vancouver style and should be numbered and listed in order of appearance in the text. In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first three followed by et al. Names of journals should be abbreviated in the style used in Index Medicus. Reference to unpublished data and personal communications should appear in the text only Titles of papers and books are to be given in the original language of publication. If citing the journal please use the abbreviation Clin. Exp. Pharmacol. Physiol.

References should be set out as follows:

Standard journal article
1. Hoka S, Takeshita A, Yamamoto K, Ito N. Effects of high salt intake on control of hindlimb vascular resistance by arterial baro-reflex and vagal afferents in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1993; 20: 663-9.

Journal article published online
2. Gonen T, Grey AC, Jacobs MD, Donaldson PJ, Kistler J. MP20, the second most abundant lens membrane protein and member of the tetraspanin superfamily, joins the list of ligands of galectin-3. BMC Cell Biol. 2001; 17: Epub 14 August 2001; doi:10.1186/1471-2121-2-17

Books and other monographs
3. Dale MM, Forman JC, Fan TP. Textbook of Immunopharmacology, 3rd edn. Blackwell Science, Oxford. 1993.

Chapter in a book
4. Williams AJ. Potassium channel openers: Clinical aspects. In: Weston AH, Hamilton TC (eds). Potassium Channel Modulators. Blackwell Science, Oxford. 1992; Ch. 17.

Electronic material
5. Bartoszewski S, Gibson JB. Injecting undechorionated eggs under ethanol. Drosophila Inform. Newslett. 1994; 14 (online). Fly-base: http://morgan.harvard.edu/fb.html [Accessed DATE] Tables Tables should be self-contained and complement but not duplicate information in the text.

Tables
should be numbered consecutively in Arabic numerals. Each table should be presented on a separate page with a comprehensive but concise legend above the table. Tables should be double-spaced and vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations should be defined in footnotes. Footnote symbols: †, ‡, § should be used (in that order) and *, **, *** should be reserved for P values. The table and its legend/footnotes should be understandable without reference to the text.

Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration.

Size. Figures will be greatly reduced in size for publication. Fonts must therefore be large and consistent and lines should be relatively thick. Authors should prepare figures to fit within the column (84 mm), or the full text width (176 mm).

Resolution. Figures must be supplied as high resolution saved as .eps or .tif.

Halftone figures: 300 dpi (dots per inch)
Colour figures: 300 dpi saved as CMYK
Figures containing text: 400 dpi
Line figures: 1000 dpi Color figures.

Files should be set up as CMYK (cyan, magenta, yellow, black) and not as RGB (red, green, blue) so that colors as they appear on screen will be a closer representation of how they will print in the journal. Figures are published in colour in the journal free of charge.

Figure legends
Type figure legends on a separate page. Legends should be concise but comprehensive. The figure and legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Further information can be obtained at: The CEPP Guidelines for Preparation of Figures: and Wiley's guidelines for preparation of figures.

Equations
Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.

Supporting Information
Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted with your manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found here. Please note that the provision of supporting information is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.



5. SUBMISSION REQUIREMENTS

A cover letter should be included in the ‘Cover Letter Field’ of the ScholarOne system. The text can be entered directly into the field or uploaded as a file. The covering letter must contain:

• An acknowledgment that all authors have contributed significantly and that all authors are in agreement with the content of the manuscript.

• In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be quantified.

• Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Brazil in 2013).

• Authors must declare any financial support or relationships that may pose conflict of interest, for more detail refer to the section ‘Disclosure’ above.

Two Word-files need to be included upon submission: A title page file and a main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including tables and figure legends but excluding figures which should be supplied separately.

The main text file should be prepared using Microsoft Word, doubled-spaced. All pages should be numbered consecutively in the top right-hand corner, beginning with the first page of the main text file.

Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files will be required.


6. PUBLICATION PROCESS AFTER ACCEPTANCE
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the Author Services and copyright and licencing options for the journal appear below.

Wiley’s Author Services: Tracking your paper’s progress Author Services also enables authors to track their article through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit Author Services for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Accepted Articles The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online very soon after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. After print publication, the DOI remains valid and can continue to be used to cite and access the article.

Proofing When the article proofs are ready, the corresponding author will receive an e-mail alert containing a link to an online proofing system. The email will include detailed instructions regarding how to mark-up corrections directly onto PDF proofs and return of corrections electronically. All annotations are saved to a remote server via a live web environment. There is no need for the author to save anything locally.

Early View The journal offers rapid speed to publication via Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before allocation to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.

Offprints A PDF reprint of the article will be supplied free of charge to the corresponding author. Additional printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: http://offprint.cosprinters.com/cos. If you have queries about offprints please e-mail: offprint@cosprinters.com.

Author Marketing Toolkit The Wiley Author Marketing Toolkit provides authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.



7. COPYRIGHT, LICENSING AND ONLINE OPEN
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.

Authors may choose to publish under the terms of the journal’s standard copyright transfer agreement (CTA), or under open access terms made available via Wiley OnlineOpen.

Standard Copyright Transfer Agreement: FAQs about the terms and conditions of the standard CTA in place for the journal, including standard terms regarding archiving of the accepted version of the paper, are available at: Copyright Terms and Conditions FAQs. Note that in signing the journal’s licence agreement authors agree that consent to reproduce figures from another source has been obtained.

OnlineOpen – Wiley’s Open Access Option: OnlineOpen is available to authors of articles who wish to make their article freely available to all on Wiley Online Library under a Creative Commons license. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made open access. Authors of OnlineOpen articles are permitted to post the final, published PDF of their article on their personal website, and in an institutional repository or other free public server immediately after publication. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

OnlineOpen licenses. Authors choosing OnlineOpen retain copyright in their article and have a choice of publishing under the following Creative Commons License terms: Creative Commons Attribution License (CC BY); Creative Commons Attribution Non-Commercial License (CC BY NC); Creative Commons Attribution Non-Commercial-NoDerivs License (CC BY NC ND). To preview the terms and conditions of these open access agreements please visit the Copyright Terms and Conditions FAQs.

Funder Open Access and Self-Archiving Compliance: Please click here for more information on Wiley’s compliance with specific Funder Open Access and Self Archiving Policies, and click here for more detailed information specifically about Self-Archiving definitions and policies.


8. CONTACT

Inquiries regarding manuscripts and peer review should be emailed to:

Editorial Office: cepp@wiley.com

Inquiries to the Editor-in-Chief should be sent to:

Professor Jun-Ping Liu
Clinical and Experimental Pharmacology and Physiology
4th Floor, Building 1, 126 Wen-Zhou Road
Hangzhou, China 310015
Tel/Fax: 86-571-88358083

Email: jun-ping.liu@monash.edu



Guidelines updated 12 May 2015

SEARCH

SEARCH BY CITATION